| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Georg Juckel, Florian Schlagenhauf, Michael Koslowski, Torsten Wüstenberg, Arno Villringer, Brian Knutson, Jana Wrase, Andreas Hein. Dysfunction of ventral striatal reward prediction in schizophrenia. NeuroImage. vol 29. issue 2. 2006-03-21. PMID:16139525. |
negative symptoms may be associated with dysfunction of the brain reward system in schizophrenia. |
2006-03-21 |
2023-08-12 |
Not clear |
| R L H Clements, A J Greensha. Facilitation of brain stimulation reward by MK-801 (dizocilpine) may be independent of D2-like dopamine receptor stimulation in rats. Psychopharmacology. vol 182. issue 1. 2006-02-22. PMID:16133130. |
dopamine (da) and glutamate (glu) interactions in the mesocorticolimbic pathway may regulate motivation and reward and contribute to schizophrenia and drug abuse. |
2006-02-22 |
2023-08-12 |
rat |
| Ester Frid. Endocannabinoids in the central nervous system: from neuronal networks to behavior. Current drug targets. CNS and neurological disorders. vol 4. issue 6. 2006-02-07. PMID:16375681. |
however, additional functions and dysfunctions such as reward and addiction, motor coordination, pain perception, feeding and appetite, coping with stress, schizophrenia and epilepsy will also be reviewed. |
2006-02-07 |
2023-08-12 |
Not clear |
| Robert M Roth, Mary F Brunette, Alan I Gree. Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Current psychiatry reports. vol 7. issue 4. 2006-01-12. PMID:16098282. |
of these, brain reward circuitry dysfunction, hypothesized to be etiologically important in suds, may be an especially salient target for treatments aimed at the reduction of substance use in patients with schizophrenia. |
2006-01-12 |
2023-08-12 |
Not clear |
| Michael Ritsner, Ehud Susse. Temperament types are associated with weak self-construct, elevated distress and emotion-oriented coping in schizophrenia: evidence for a complex vulnerability marker? Psychiatry research. vol 128. issue 3. 2005-04-15. PMID:15541778. |
we found that the harm avoidance (ha) factor was higher, while reward dependence (rd) was lower in schizophrenia patients than in healthy controls. |
2005-04-15 |
2023-08-12 |
Not clear |
| Douglas L Noordsy, Alan I Gree. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Current psychiatry reports. vol 5. issue 5. 2004-01-06. PMID:13678553. |
the confluence of findings is consistent with a model of a reward dysfunction inherent in the neuropathology of schizophrenia, leading to a heightened vulnerability of people with schizophrenia to substance use disorders. |
2004-01-06 |
2023-08-12 |
Not clear |
| Michael H Joseph, Krishna Datla, Andrew M J Youn. The interpretation of the measurement of nucleus accumbens dopamine by in vivo dialysis: the kick, the craving or the cognition? Neuroscience and biobehavioral reviews. vol 27. issue 6. 2003-12-18. PMID:14599434. |
psychopharmacological studies have implicated the dopaminergic innervation of the nucleus accumbens (nac) in reward and reinforcement, in the actions of addictive drugs, and in the control of the symptoms of schizophrenia. |
2003-12-18 |
2023-08-12 |
rat |
| S Potvin, E Stip, J-Y Ro. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis]. L'Encephale. vol 29. issue 3 Pt 1. 2003-09-17. PMID:12876543. |
however, from a biological perspective, substance abuse among schizophrenic patients appears paradoxical: while the positive symptoms of schizophrenia might involve an hyperactivity of the reward system, the drugs of abuse all seem to increase dopamine release in that same system. |
2003-09-17 |
2023-08-12 |
Not clear |
| Cecile Spielewoy, Athina Marko. Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 28. issue 6. 2003-08-04. PMID:12700700. |
these results indicate that prolonged continuous administration of high pcp doses facilitates brain stimulation reward, while withdrawal from acute high pcp doses or chronic pcp treatment results in a protracted depression of brain reward function that may be analogous to the dysphoric and anhedonic symptoms observed in pcp dependence, depression, and schizophrenia. |
2003-08-04 |
2023-08-12 |
rat |
| Alan I Green, Melinda S Salomon, Mark J Brenner, Kimberly Rawlin. Treatment of schizophrenia and comorbid substance use disorder. Current drug targets. CNS and neurological disorders. vol 1. issue 2. 2003-06-18. PMID:12769622. |
while the basis for the increased abuse of alcohol and other substances in patients with schizophrenia have been linked by some investigators to "self-medication" of negative symptoms of schizophrenia or extrapyramidal system effects of typical antipsychotics, we have presented a neurobiologic formulation suggesting that alcohol or other substances may transiently correct a dysfunction of the dopamine-mediated mesocorticolimbic pathways in patients with schizophrenia - pathways linked to brain reward circuits. |
2003-06-18 |
2023-08-12 |
Not clear |
| Henrike Neuhoff, Axel Neu, Birgit Liss, Jochen Roepe. I(h) channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 22. issue 4. 2002-02-26. PMID:11850457. |
dopaminergic (da) midbrain neurons in the substantia nigra (sn) and ventral tegmental area (vta) are involved in various brain functions such as voluntary movement and reward and are targets in disorders such as parkinson's disease and schizophrenia. |
2002-02-26 |
2023-08-12 |
mouse |
| R A Chambers, J H Krystal, D W Sel. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological psychiatry. vol 50. issue 2. 2001-12-10. PMID:11526998. |
however, recent advances suggest that increased vulnerability to addictive behavior may reflect the impact of the neuropathology of schizophrenia on the neural circuitry mediating drug reward and reinforcement. |
2001-12-10 |
2023-08-12 |
Not clear |
| T M Tzschentk. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Progress in neurobiology. vol 63. issue 3. 2001-03-01. PMID:11115727. |
these include reward and addiction, locomotor activity and sensitization, learning, cognition, and schizophrenia. |
2001-03-01 |
2023-08-12 |
rat |
| M Harrow, C A Yonan, J R Sands, J Mareng. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophrenia bulletin. vol 20. issue 2. 1994-10-11. PMID:8085135. |
these data suggest that one factor involved in the depressive-like symptoms found in schizophrenia patients could be interference by neuroleptics with the mesolimbic dopamine reinforcement system or the dopamine reward system. |
1994-10-11 |
2023-08-12 |
Not clear |
| R Mille. Striatal dopamine in reward and attention: a system for understanding the symptomatology of acute schizophrenia and mania. International review of neurobiology. vol 35. 1993-05-05. PMID:8463061. |
striatal dopamine in reward and attention: a system for understanding the symptomatology of acute schizophrenia and mania. |
1993-05-05 |
2023-08-12 |
Not clear |
| R Sandyk, S R Ka. Tobacco addiction as a marker of age at onset of schizophrenia. The International journal of neuroscience. vol 57. issue 3-4. 1991-12-03. PMID:1938168. |
since addictive behaviour may be related to decreased dopamine activity in the mesolimbic reward circuitry, we predict a higher prevalence of tobacco addiction in patients with an earlier age at onset of schizophrenia. |
1991-12-03 |
2023-08-11 |
Not clear |
| S Yamagami, K Soejim. Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia. Drugs under experimental and clinical research. vol 15. issue 4. 1989-10-23. PMID:2570687. |
these results suggest that maprotiline improves the negative symptoms of schizophrenia by a noradrenaline potentiating action not demonstrated by dopaminergic or serotonergic reward systems. |
1989-10-23 |
2023-08-11 |
Not clear |
| S D Glick, L M Weaver, R C Meibac. Amphetamine enhancement of reward asymmetry. Psychopharmacology. vol 73. issue 4. 1981-09-15. PMID:6789352. |
it is proposed that schizophrenia results from a lateralized overactivity of dopaminergic neuronal systems mediating reward and that amphetamine mimics schizophrenic symptomatology by enhancing lateralization of the same systems. |
1981-09-15 |
2023-08-12 |
rat |
| T J Cro. Catecholamine reward pathways and schizophrenia: the mechanism of the antipsychotic effect and the site of the primary disturbance. Federation proceedings. vol 38. issue 11. 1979-12-18. PMID:39790. |
catecholamine reward pathways and schizophrenia: the mechanism of the antipsychotic effect and the site of the primary disturbance. |
1979-12-18 |
2023-08-11 |
Not clear |
| L Stei. Norepinephrine reward pathways: role of self-stimulation, memory consolidation, and schizophrenia. Nebraska Symposium on Motivation. Nebraska Symposium on Motivation. vol 22. 1976-03-15. PMID:1688. |
norepinephrine reward pathways: role of self-stimulation, memory consolidation, and schizophrenia. |
1976-03-15 |
2023-08-11 |
Not clear |